Immune Checkpoint Inhibitor Rechallenge After Immune‐Related Adverse Events: A Systematic Review and Meta‐Analysis
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72450 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Medicine, online erschienen am 05.11.2026. Verfasst von Xinwei Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The People's Hospital of Renshou County, Meishan, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Technology Department of Sichuan Provincial Science and Central Guidance Local Exploration Fund Project.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Restarting immune checkpoint inhibitors (ICIs) after an immune‐related adverse event (irAE) requires balancing toxicity against antitumor benefit. Prior reviews often mixed post‐irAE restart with retreatment after progression or combined cohorts with case reports. This systematic review evaluated cohort evidence on ICI restart after irAE‐related interruption.
Methods
PubMed/MEDLINE, Embase, Web of Science Core Collection, Scopus, CENTRAL, and reference lists were searched through 24 April 2026 for observational clinical cohort studies. Primary outcomes were index‐irAE recurrence, any post‐rechallenge irAE (recurrent or new), and grade ≥ 3 post‐rechallenge irAE (recurrent or new). Secondary outcomes included toxicity‐related discontinuation, objective response, disease control, overall survival, and progression‐free survival.
Results
Thirty‐five cohorts comprising 1551 rechallenged patients were included; endpoint‐specific denominators varied. Index‐irAE recurrence was 25.4% (95% confidence interval [CI], 21.4–29.7; 30 studies). Any post‐rechallenge irAE (recurrent or new) was 44.2% (95% CI, 37.8–50.8; 23 studies). Grade ≥ 3 post‐rechallenge irAE (recurrent or new) was 19.8% (95% CI, 15.3–25.1; 22 studies). Toxicity‐related discontinuation was 25.3%. Pooled objective response and disease control were 44.3% and 72.7%, respectively. Survival data were available from nine studies for overall survival and four studies for progression‐free survival. Hazard ratios were displayed individually, and no summary hazard ratio was calculated.
Conclusions
ICI rechallenge after irAE‐related interruption was accompanied by frequent post‐rechallenge toxicity, while objective response and disease control remained evident after treatment resumption. These estimates inform individualized risk–benefit assessment and identify irAE phenotype, recovery status, and rechallenge strategy as priorities for prospective evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The People's Hospital of Renshou County, Meishan, China.
- Department of Medical Affairs, The People's Hospital of Renshou County, Meishan, China.
- Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Department of Respiratory and Critical Care Medicine, First People's Hospital of Neijiang, Neijiang, China.
- Department of Oncology, First People's Hospital of Neijiang, Neijiang, China.
- Department of Oncology, Gulin County People's Hospital, Luzhou, China.
ORCID-Profile: Xinwei Chen, Xialin Zhang, Ran Cui, Cheng Ma, Xinlin Yu, Sijie Li
Förderung
- Technology Department of Sichuan Provincial Science and Central Guidance Local Exploration Fund Project
Zitieren
APA
Chen, X., Gao, S., Zhang, X., Cui, R., Ma, C., Yu, X., & Li, S. (2026). Immune Checkpoint Inhibitor Rechallenge After Immune‐Related Adverse Events: A Systematic Review and Meta‐Analysis. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72450
Vancouver
Chen X, Gao S, Zhang X, Cui R, Ma C, Yu X, et al. Immune Checkpoint Inhibitor Rechallenge After Immune‐Related Adverse Events: A Systematic Review and Meta‐Analysis. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72450
BibTeX
@article{Chen2026,
author = {Chen, Xinwei and Gao, Shun and Zhang, Xialin and Cui, Ran and Ma, Cheng and Yu, Xinlin and Li, Sijie},
title = {Immune Checkpoint Inhibitor Rechallenge After Immune‐Related Adverse Events: A Systematic Review and Meta‐Analysis},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72450}
}
EUVIMED